Physician profile
Alan K Bugg
NPI 1871547455
$973.88
in general payments reported to CMS, 2019-2025
14 companies · $66.70 in 2025
The $66.70 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $47.69 · 2021: $83.69 · 2022: $219 · 2023: $127 · 2024: $93.82 · 2025: $66.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $287.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $402.09 | 2019-2024 | Precision 1, Total30 |
| Shire North American Group INC | $174.81 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $53.75 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $51.83 | 2022-2025 | |
| Rxsight INC | $49.72 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Coopervision INC. | $47.93 | 2022-2023 | Myday Contact Lens |
| Sight Sciences, INC. | $47.69 | 2020 | |
| Mallinckrodt Hospital Products INC. | $42.55 | 2025 | Acthar |
| Allergan, INC. | $27.60 | 2022 | |
| Vyera Pharmaceuticals, LLC | $21.76 | 2019 | |
| Oyster Point Pharma, INC. | $16.89 | 2023 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $14.96 | 2019 | |
| Abbvie INC. | $12.07 | 2022 | |
| Lombart Brothers, INC. | $10.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Bugg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.